They got $4m, they spent $4m during the quarter. Assuming that is average spending, they are left with $5m and likely $3.2m from the raising that closed yesterday. About 2 quarters left, meaning another raising or donation needed in 3-6 months.
Normally they announce only the first patient dosed but the CDH17 trial is different. 6 patients were planned by end of March, still waiting for patient 5 to be dosed and still 10 to come according to today's anns.
"CHM CDH17 is the world’s first anti-CDH17-directed CAR-T therapy and has demonstrated strong preclinical evidence, including complete eradication of tumours in multiple cancer types. The Phase 1 segment aims to enrol up to 15 patients to determine safety and optimal dosage, with four patients dosed and five successful manufacturing runs completed thus far."
That will still take years from here, can't imagine Hopper to continue this way to struggle from quarter to quarter. Either asset sale or partnerships, otherwise this will go under. And so far not one interested in any asset. More than a "Resurrection" needed.
GLTA
CHM Price at posting:
0.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)